CoChat

Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome.

Van Cutsem, E., Lang, I., Folprecht, G., Nowacki, M., Barone, C., Shchepotin, I., Maurel, J., Cunningham, D., Celik, I., Kohne, C. · 2010 · Journal of Clinical Oncology
Cited by 61

The DOI matches its Crossref record.

Abstract

3570 Background: The phase III CRYSTAL study showed that patients (pts) with KRAS wild-type (wt) tumors benefit from the addition of cetuximab to FOLFIRI as first-line treatment for metastatic colorectal cancer (mCRC). BRAF is a downstream effector of KRAS. Methods: Tumor KRAS and BRAF mutation status (wt or mutant [mt]) was determined for an expanded patient population using polymerase chain reaction and melting curve assays. Treatment arms were compared according to mutation status (log rank and Cochran-Mantel-Haenszel tests). Results: Of 1,198 pts in the primary analysis population, 1,063 (89%) were evaluable for KRAS mutation status; double the previous ascertainment rate. In pts with KRAS wt tumors, all efficacy endpoints were significantly improved in pts receiving cetuximab + FOLFIRI compared with FOLFIRI alone. Tumor BRAF status was evaluable in 625/666 pts with KRAS wt tumors. BRAF mutation was a marker of poor prognosis in both treatment arms (see Table). Conclusions: For all efficacy endpoints, including survival, this analysis confirms the value of KRAS mutational status as a predictor of treatment outcome in pts with mCRC receiving cetuximab plus FOLFIRI first-line. BRAF mutation status does not appear to be a strong predictive biomarker for the addition of cetuximab to FOLFIRI but the sample size may be too small to be conclusive. KRAS wt n=666 KRAS wt/BRAF wt n= 566 KRAS wt/BRAF mt n=59 FOLFIRI n=350 Cetuximab + FOLFIRI n= 316 FOLFIRI n=289 Cetuximab + FOLFIRI n=277 FOLFIRI n=33 Cetuximab + FOLFIRI n= 26 Median OS months ([95% CI) 20.0 (17.4–21.7) 23.5 (21.2–26.3) 21.6 (20.0–24.9) 25.1 (22.5–28.7) 10.3 (8.4–14.9) 14.1 (8.5–18.5) Hazard ratio (95% CI) 0.796 (0.670–0.946) 0.830(0.687–1.004) 0.908(0.507–1.624) p 0.0093 0.0549 0.7440 Median PFS months(95% CI) 8.4 (7.4–9.2) 9.9 (9.0–11.3) 8.8 (7.6–9.4) 10.9 (9.4–11.8) 5.6 (3.5–8.1) 8.0 (3.6–9.1) Hazard ratio (95% CI) 0.696 (0.558–0.867) 0.679 (0.533–0.864) 0.934 (0.425–2.056) p 0.0012 0.0016 0.8656 OR rate (%) (95% CI) 39.7 (34.6–45.1) 57.3 (51.6–62.8) 42.6 (36.8–48.5) 61.0 (55.0–66.8) 15.2 (5.1–31.9) 19.2 (6.6–39.4) Odds ratio (95% CI) 2.0693 (1.5154–2.8258) 2.1750 (1.5505–3.0511) 1.0842 (0.2644–4.4456) p <0.0001 <0.0001 0.9136 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Merck KGaA Merck KGaA/Merck Serono Amgen, Merck KGaA/Merck Serono, Merck Serono, Pfizer, Roche, sanofi-aventis Merck Serono, Pfizer, sanofi-aventis

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.28.15_suppl.3570

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 61

Metadata

Authors
Van Cutsem, E., Lang, I., Folprecht, G., Nowacki, M., Barone, C., Shchepotin, I., Maurel, J., Cunningham, D., Celik, I., & Kohne, C.
Venue
Journal of Clinical Oncology
Published
2010-05-20
Volume
28
Issue
15_suppl
Pages
3570-3570
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2591284091
Cited by
61
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. https://app.cochat.ai/papers/10.1200/jco.2010.28.15_suppl.3570
The paper
Van Cutsem, E., Lang, I., Folprecht, G., Nowacki, M., Barone, C., Shchepotin, I., Maurel, J., Cunningham, D., Celik, I., & Kohne, C. (2010). Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.28.15_suppl.3570

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.